BTK and B-cell chronic lymphocytic leukemia: Accordingly, either genetic deletion of the BTK gene or inhibition of BTK by ibrutinib in the Eμ‐TCL1 mouse model significantly delays the onset of CLL (Woyach et al, 2014).